Serac Healthcare

Serac Healthcare is a clinical radiopharmaceutical company developing 99mTc-maraciclatide, an innovative molecular imaging agent with FDA Fast Track Designation for the diagnosis and visualisation of superficial peritoneal endometriosis. Phase 2 data published in The Lancet Obstetrics, Gynaecology and Women's Health demonstrate maraciclatide's potential as a non-invasive diagnostic tool for endometriosis, including superficial peritoneal disease which is not reliably detected by conventional imaging, with applications in disease monitoring, treatment response assessment, and novel therapy development.